Company Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Employees

Sector

Biotechnology & Medical Research

More about the company

24/06/24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
13/05/24	Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	CI
14/10/23	Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	CI
27/01/23	Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	CI
12/12/22	Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	CI
23/02/22	Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	CI
16/12/21	Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	CI
18/11/21	Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	CI
12/10/21	CombiGene in Billion-Dollar Deal with Spark Therapeutics	CI
07/09/21	NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	CI
21/07/21	Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	CI
13/04/21	Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	CI
25/02/21	Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	CI

11/04/23	One of Nature’s journals publishes article about CombiGene’s epilepsy project	AQ
30/01/23	Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	AQ
30/01/23	Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	AQ
17/05/22	Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	AQ
10/05/22	CombiGene presents at Aktiedagen Göteborg on Monday 16 May	AQ

12/12/22	Roche: Gentherapie SPK-8011 von Tochter Spark erweist sich als dauerhaft wirksam
18/12/19	Roche-Chef will aus Spark ein Exzellenzzentrum für Gentherapie machen
17/12/19	Roche exécute son offre sur Spark Therapeutics
17/12/19	Spark Therapeutics : Roche finalise son acquisition
17/12/19	Roche officialise la finalisation de la reprise de Spark Therapeutics

Manager	Title	Age	Since
Sylke Poehling CEO	Chief Executive Officer	-	09/09/2024
Michael Retterath PRN	Corporate Officer/Principal	-	16/11/2020

Director	Title	Age	Since
Bruce Resnick BRD	Director/Board Member	-	17/12/2019
Sean Johnston BRD	Director/Board Member	-	17/12/2019

Spark Therapeutics, Inc. Stock

Stocks

US84652J1034

Biotechnology & Medical Research

Latest news : Spark Therapeutics, Inc.

Press Releases: Spark Therapeutics, Inc.

News in other languages: Spark Therapeutics, Inc.

Managers and Directors: Spark Therapeutics, Inc.

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPARK THERAPEUTICS, INC.	-.--%	-.--%	-	-	4.38B
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+69.74%	+109.30%	68.12B
ARGENX SE	+1.25%	+2.44%	+32.55%	+72.63%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.95%	+499.45%	28.63B
BIONTECH SE	+2.72%	+3.41%	-15.88%	-4.90%	23.53B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	23.99B
GENMAB A/S	+6.50%	+7.56%	+38.20%	-21.33%	18.45B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+354.30%	15.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	16.44B
EXELIXIS, INC.	+3.58%	+1.96%	+44.61%	+167.01%	13.4B
Average	+3.46%	+11.68%	+52.91%	+206.99%	29.28B
Weighted average by Cap.	+4.29%	+13.10%	+49.48%	+168.49%